Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
Hand-out
Press Releases
Syndax Pharmaceuticals, Inc.  
November 4, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib

avatar profile Olean Times Herald

Olean Times Herald


Local & Social